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Abstract
Objectives The aim was to document, from the perspec-
tive of the empirical literature, the primary symptoms of
functional dyspepsia (FD), evaluate the extent to which
existing questionnaires target those symptoms, and, finally,
identify any missing evidence that would impact the
questionnaires’ use in regulated clinical trials to assess
treatment efficacy claims intended for product labeling.
Methods A literature review was conducted to identify
the primary symptoms of FD and existing symptom-based
FD patient-reported outcome (PRO) instruments. Follow-
ing a database search, abstracts were screened and articles
were retrieved for review. The primary symptoms of FD
were organized into a conceptual model and the PRO
instruments were evaluated for conceptual coverage as well
as compared against evidentiary requirements presented in
the FDA’s PRO Guidance for Industry.
Results Fifty-six articles and 16 instruments assessing FD
symptoms were reviewed. Concepts listed in the Rome III
criteria for FD (n = 7), those assessed by existing FD
instruments (n = 34), and symptoms reported by patients
in published qualitative research (n = 6) were summarized
in the FD conceptual model. Except for vomiting, all of the
identified symptoms from the published qualitative
research reports were also specified in the Rome III crite-
ria. Only three of the 16 instruments, the Dyspepsia
Symptom Severity Index (DSSI), Nepean Dyspepsia Index
(NDI), and Short-Form Nepean Dyspepsia Index (SF-NDI),
measure all seven FD symptoms defined by the Rome III
criteria. Among these three, each utilizes a 2-week recall
period and 5-point Likert-type scale, and had evidence of
patient involvement in development. Despite their cover-
age, when these instruments were evaluated in light of
regulatory expectations, several issues jeopardized their
potential qualification for substantiation of a labeling
claim.
Conclusions No existing PRO instruments that measured
all seven symptoms adhered to the regulatory principles
necessary to support product labeling. As such, the devel-
opment of a new FD symptom PRO instrument is
supported.
Key Points for Decision Makers
There are no functional dyspepsia-specific clinical
outcome assessments that have adequate
documentation to support their use for US labeling
purposes in regulated clinical trials.
There is a need for the development of a new clinical
outcome assessment for patients with functional
dyspepsia that reflects the preliminary conceptual
model proposed by the authors.
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Functional dyspepsia (FD) is a complex disorder defined by
upper gastrointestinal symptoms, including epigastric pain
and burning, postprandial fullness, early satiation, bloating,
belching, nausea, and vomiting, outside of any evident
structural disease [1]. The definition of FD will likely
continue to evolve with the publication of the revised
Rome IV diagnostic criteria in 2016 [2]; however, the
current definition, formulated by the Rome task force in
2006 as part of Rome III, includes two subtypes, post-
prandial distress syndrome and epigastric pain syndrome,
that may overlap to varying degrees [3]. Postprandial dis-
tress syndrome is characterized by postprandial fullness
and early satiation, and epigastric pain syndrome is char-
acterized by epigastric pain and burning. Given the current
definition, the prevalence of FD as defined in Rome III is
difficult to determine because, based on the diagnostic
criteria, an upper endoscopy must be performed to rule out
the presence of any structural disease [3]. As a result, the
literature commonly reports the prevalence of ‘‘uninvesti-
gated dyspepsia,’’ with estimates ranging from 5 to 15 %
depending on the population and definition used within
individual studies [1].
The Critical Path Institute’s Patient-Reported Outcome
(PRO) Consortium [4], in conjunction with advisors from
the US Food and Drug Administration (FDA), has identi-
fied the need for a well-defined and reliable patient-re-
ported instrument to assess treatment benefit in FD clinical
trials. Although self-reporting is central to identifying and
evaluating treatments for this symptom-defined condition,
it is unclear to what extent the development of existing FD
symptom PRO questionnaires was consistent with the
FDA’s Guidance for Industry, ‘‘Patient-Reported Outcome
Measures: Use in Medical Product Development to Support
Labeling Claims’’ (hereafter referred to as ‘‘FDA PRO
Guidance’’) [5]. Therefore, the PRO Consortium estab-
lished the Functional Dyspepsia Working Group (WG) to
develop a PRO instrument for use as a primary endpoint
assessment in FD clinical trials, and to submit the instru-
ment for qualification under the FDA’s Drug Development
Tools (DDT) Qualification Program [6].
As a first step, the WG set out to develop the evidentiary
basis for the construction of a new PRO instrument to
evaluate FD treatment efficacy claims. To this end, both a
symptoms review and an instrument review were con-
ducted. In keeping with the FDA PRO Guidance [5], the
objectives of these activities were to document, from the
perspective of the empirical literature, the primary symp-
toms of FD, evaluate the extent to which existing ques-
tionnaires target those symptoms, and, finally, identify any
missing evidence that would impact the questionnaires’ use
in regulated clinical trials to assess treatment efficacy
claims intended for product labeling. To the extent that
existing instruments did not measure the concepts of
interest (i.e., the primary symptoms of FD) or failed to
meet the FDA’s evidentiary standards, decisions could be
informed with respect to developing a new instrument or
repurposing an existing one. In that light, it is important to
note that the FDA categorizes a ‘‘questionnaire’’ as a set of
questions or items shown to a respondent to obtain answers
for research purposes, while an ‘‘instrument’’ consists of
both a means to capture data (i.e., a questionnaire) plus all
the information and documentation that supports its use
(e.g., methods and instructions for administration or
responding, a standard format for data collection, and
methods for scoring, analysis, and interpretation of results)
[5].
2 Methodology
2.1 Symptoms and Instrument Literature Searches
Literature searches were conducted in the Embase,
PsycINFO, and MEDLINE databases, using the OvidSP
platform. Searches were limited to English-language
studies in humans. To prevent the aggregation of unrelated
or previously misclassified diseases, search results were
also limited to those conducted from January 2006 onward,
the year the Rome III criteria [3] for FD were published;
and the search results closed May 2013, after which our
instrument development transitioned to qualitative
research. Search terms included ‘‘functional dyspepsia,’’
‘‘nonulcer dyspepsia,’’ ‘‘idiopathic dyspepsia,’’ ‘‘essential
dyspepsia,’’ ‘‘postprandial distress syndrome,’’ and ‘‘epi-
gastric pain syndrome’’; these were required to be present
in the abstract of the article. In addition, abstracts were
required to include at least one search term related to
symptoms, questionnaires, or qualitative research methods.
A manual inspection of the reference lists of all retrieved
articles was also performed to identify any relevant cita-
tions not captured with the specified search criteria.
Search results were screened by abstract for relevancy
and retrieved for full review according to pre-defined eli-
gibility criteria. Specifically, articles were selected for
review if they were specific to FD in adults, referenced
symptoms of FD as experienced by patients, or referenced
FD symptom-specific questionnaires or published qualita-
tive research with patients (i.e., referenced qualitative
design/methodology/analysis, such as interviews, focus
groups, or patient reports); articles were excluded if they
concerned FD in a pediatric population, concerned symp-
tom assessment in a mixed population (i.e., population was
not exclusive to patients with FD and included patients
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with other gastrointestinal conditions), reported data on
patients recruited into a study based on pre-Rome II cri-
teria, reported FD symptoms without specifying a quali-
tative methodology or naming a specific questionnaire by
which they were collected, focused on questionnaires used
for diagnostic purposes only (not study endpoints), or were
derived from non-peer-reviewed research (e.g., conference
proceedings or dissertations). From each article selected for
full-text review, data pertaining to the study aim, sample
demographics, methodology, and results were extracted by
populating a data extraction spreadsheet with these pre-
specified variables.
In addition to the review of the literature, the patient-
reported outcome and quality of life instruments database
(PROQOLID) was searched to identify existing PRO
instruments used to measure FD symptoms. PROQOLID is
a database of PRO instruments managed by the Mapi
Research Trust [7]. It includes information on psychome-
tric properties, development and validation, available
translations, and conditions of use from over 1000 reports
on PRO instruments. Questionnaires focusing on or com-
prising domains focusing on the assessment of the patient
experience of FD symptoms were considered for review.
Questionnaires evaluating the impacts of FD, or health-
related quality of life or quality of life, were excluded, as
were any questionnaires not available in English.
2.2 Conceptual Model Development
Collectively, symptom concepts (e.g., epigastric pain and
burning) identified in each of the reviewed articles were
used to construct a preliminary conceptual model of the
symptom experience of FD [8]. For comprehensiveness,
the conceptual model included all concepts reported from
each of the three sources, including existing PRO instru-
ments, published qualitative research, and the Rome III
criteria [8–10]. The published qualitative research included
documented instances of symptom concepts spontaneously
reported by patients with FD. Published interviews, focus
groups, or written reports in which patients were allowed to
freely expound outside the confines of a previously
described or developed instrument were all considered
eligible for analysis.
Proposed by Wilson and Cleary [8], a conceptual model
is a heuristic classification scheme that links a specified
disease state or condition to its proximal and increasingly
distal health outcomes. In general, proximal concepts tend
to be uni-dimensional, have a direct relationship with the
condition and effects of treatment, and have greater
potential to be characterized by primary trial outcomes.
Distal concepts tend to be multi-dimensional, indirectly
related to the condition and effects of treatment, and have
less potential to be characterized by primary trial outcomes
[9, 10]. In the present context, the preliminary conceptual
model was intended to capture only proximal, condition-
level concepts (i.e., symptoms of FD).
2.3 Instrument Evaluation
Following the instrument literature review, existing PRO
instruments were evaluated using a two-step approach.
First, the adequacy of concept coverage was evaluated by
comparing the concepts assessed by the reviewed instru-
ments to the primary FD symptoms specified in the Rome
III criteria (postprandial fullness, early satiation, post-
prandial nausea, excessive belching, epigastric pain, epi-
gastric burning, and upper abdominal bloating) [3].
Second, instruments deemed to have adequate conceptual
coverage were further evaluated against the evidentiary
requirements set forth in the FDA PRO Guidance [5], and
Clinical Outcome Assessment (COA) criteria established
by the FDA’s Study Endpoints and Label Development
(SEALD) group [11].
3 Results
3.1 Symptoms Literature Search
The literature search identified a total of 787 articles.
Through the initial database search (Embase,
PsycINFO, and MEDLINE), 780 potentially relevant
articles were identified. Subsequently, seven additional
articles were added from the article reference lists; 56
articles were included in the final review (Fig. 1).
3.2 Conceptual Model for Functional Dyspepsia
Symptoms
The FD symptom conceptual model derived from the
symptoms literature review is presented in Fig. 2 (depicted
as a Venn diagram). The bottom left circle (a) of the model
contains those concepts listed in the Rome III criteria for
FD [3]. The top circle (b) contains the additional concepts
assessed in existing questionnaires, which largely fall into
one of two distinct categories: irritable bowel syndrome
(IBS)-like symptoms [3] and heartburn or gastroesophageal
reflux disease (GERD)-like symptoms [12]. Other dys-
peptic symptoms that did not fit into one of these two
categories are listed separately. Heartburn or GERD-like
symptoms have been shown to co-occur with dyspeptic
symptoms and are deemed interconnected to the key
diagnostic symptoms of FD [1]. Further, patients with FD
frequently experience IBS-like symptoms, making it diffi-
cult to separate IBS from the symptoms used as diagnostic
criteria of FD.
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Finally, the bottom right circle (c) contains the symp-
toms reported by patients with FD in published qualitative
research (non-instrument-based). These concepts include
five of the diagnostic criteria from Rome III [3]—post-
prandial fullness, postprandial nausea, excessive belching,
epigastric pain, and upper abdominal bloating—as well as
vomiting. Excluding the articles describing the develop-
ment of FD instruments, only one article was identified that
describes spontaneous patient reports of FD symptoms
[13]. In this study, which examined the relationship
between FD symptoms and dietary patterns, 41 patients
[n = 20 with FD (17 women; mean age = 45 ± 3 years;
age range = 23–73 years) and n = 21 healthy controls (18
women; mean age = 40 ± 4 years; age range = 20–74 -
years)] completed symptom diaries in which they recorded
any symptoms experienced, their severity, and the time at
which they occurred. Subjects reported a total of 612
symptoms, which were divided into meal-related, meal-
unrelated, or other symptoms on the basis of the time of
their occurrence. Meal-related symptoms were reported as
bloating, nausea, upper-abdominal pain, belching, epigas-
tric pain, fullness, vomiting, and discomfort. Information
on other symptom categories was not reported. With the
exception of vomiting, all meal-related symptoms were
redundant with the Rome III diagnostic criteria [3].
3.3 Instrument Evaluation: Conceptual Coverage
of Functional Dyspepsia Instruments
A total of 16 PRO instruments assessing symptoms of FD
were identified. The conceptual coverages of these instru-
ments were evaluated against the seven primary symptom
concepts defined by the Rome III criteria [3]. A total of
three instruments were found to measure all seven symp-
toms: the Dyspepsia Symptom Severity Index (DSSI),
Nepean Dyspepsia Index (NDI), and Short-Form Nepean
Dyspepsia Index (SF-NDI). A summary of the conceptual
coverages of the identified FD instruments is provided in
Table 1.
Of the seven primary symptoms of FD, the most com-
monly measured by existing FD instruments were post-
prandial nausea/nausea and epigastric pain/pain, with 13
out of 16 instruments containing items assessing these two
symptoms. Eleven of the 16 instruments also had items
measuring ‘‘upper abdominal bloating’’ or ‘‘bloating.’’
Among the 13 instruments with incomplete conceptual
coverage of the seven primary FD symptoms, ‘‘epigastric
burning’’ and ‘‘postprandial fullness’’ were the symptoms
most often omitted from assessment (omitted in 11 and ten
instruments, respectively).
3.4 Instrument Evaluation: Description
and Developmental History of Functional
Dyspepsia Instruments
Instruments concluded to have adequate conceptual cov-
erage—the DSSI, NDI, and SF-NDI—were further evalu-
ated with regard to the instruments’ recall periods, item
wording, response options, scoring, and development his-
tories (Table 2).
Recall period An instrument’s recall period is defined as
the time period that respondents are asked to consider when
replying to items. The DSSI, NDI, and SF-NDI all utilize
recall periods of the 2 weeks prior to assessment. The FDA
has indicated, particularly for symptom assessment (i.e.,
concepts that vary over short periods of time), that recall
periods that ask respondents to focus on their current or
recent state (e.g., the past 24 h) are preferable to longer
intervals [5]. If FD symptoms vary within a day and/or
between days, the instruments reviewed here may raise
concern due to potential recall bias and an inability to
account for daily variation in FD symptoms.
Item wording An item was considered well-constructed
based on the following criteria: contains no medical jargon
or slang, double negatives, or overlapping or unbalanced
responses; assesses only one concept (i.e., not double-
barreled); and does not assess vague or ambiguous con-
cepts. Item wording was deemed adequate in both the full
Citations identified in Embase®, 
PsycINFO®, and MEDLINE® search for 
articles published from 01/01/2006
through 05/03/2013
(n=780)
Abstracts failing to 
meet criteria*
(n=727)
Articles retrieved for full-text review
(n=53) Additional relevant 
articles identified





Articles failing to 
meet criteria*
(n=4)
Fig. 1 Symptoms literature search flow diagram. Asterisk articles
were excluded if they concerned FD in a pediatric population, a
mixed population (i.e., not exclusive to FD), reported data on patients
recruited into a study based on pre-Rome II criteria, reported FD
symptoms without specifying a qualitative methodology or naming a
specific questionnaire by which they were collected, focused on
questionnaires used for diagnostic purposes only, or were derived
from non-peer-reviewed research. FD functional dyspepsia
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and short forms of the NDI; however, the DSSI includes an
item assessing ‘‘discomfort,’’ which may be best measured
with multiple items assessing various dimensions of
‘‘discomfort.’’
Response options Response options comprise the range of
choices a questionnaire provides to respondents in replying
to individual items. The DSSI, NDI, and SF-NDI all use
5-point Likert-type scales. For the DSSI, the wording of
response options was considered clear and appropriate, and
response options were appropriately ordered, with strong
distinctions offered between choices.
The NDI, however, uses a ‘‘bother’’ scale to assess
symptoms, in addition to frequency and intensity scales,
and scoring involves the summation of frequency, inten-
sity, and bother scores. Incorporating bother scores may
raise concerns because bother is a complex evaluative
concept that may encompass aspects of symptom fre-
quency, severity, and associated impact. Additionally,
greater opportunity for individual variation exists among
participants responding to a measure of symptom bother
than for items assessing symptom frequency or severity.
Moreover, how individual patients arrive at different
responses is potentially unclear. The use of ‘‘bother’’ may
also prove difficult to implement in global trials, where
translation of the instrument will likely be required [31].
Finally, incorporating multiple scales in one instrument
may raise concerns, as certain symptoms lend themselves
to assessment along particular dimensions better than oth-
ers. For example, patients may find it more difficult to
assess vomiting in terms of intensity rather than frequency;
therefore, the assessment of both frequency and intensity in
the NDI may be problematic for some symptoms.
Development history An instrument’s development history
consists of the methods used to inform its construction. The
DSSI, NDI, and SF-NDI provided some evidence indicat-
ing patient involvement in their development. However,
few details were provided concerning the characteristics of
the participant populations used and the way in which data
generated from these activities informed item develop-
ment. Furthermore, no reference to ‘‘concept saturation’’
(i.e., the point at which no new information would likely be
generated upon conduct of additional interviews, a measure
Fig. 2 Conceptual model for FD symptoms. Qualitative patient
reports from Pilichiewicz et al. [13]. Asterisk postprandial distress
syndrome symptoms, as defined by Rome III criteria. Dagger
epigastric pain syndrome symptoms, as defined by Rome III criteria.
FD functional dyspepsia, GERD gastroesophageal reflux disease, IBS
irritable bowel syndrome, PRO patient-reported outcome
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of confidence in qualitative research results) was made in
any of the instrument development papers. In light of these
findings, further evidence is needed to confirm that the
instruments adequately assess all symptoms relevant and
important to an FD-specific population.
4 Discussion
Functional dyspepsia is a complex disorder defined by
upper gastrointestinal symptoms, including epigastric pain
and burning, postprandial fullness, early satiation, bloating,
belching, nausea, and vomiting, outside of any evident
structural disease. Despite the centrality of patient assess-
ment in properly identifying patients and evaluating treat-
ments for this symptom-defined condition, it is unclear to
what extent existing PRO instruments for assessing
symptoms of FD were developed according to principles
consistent with the approach outlined in the FDA PRO
Guidance for supporting product labeling. In keeping with
the FDA PRO Guidance approach, the objectives of our
symptoms and instrument literature reviews were to doc-
ument, from the perspective of the empirical literature, the
primary symptoms of FD, evaluate the extent to which
existing instruments target those symptoms, and, finally,
identify any missing evidence that would impact their use
in product labeling.
The identified symptoms of FD are summarized in the
preliminary conceptual model and include symptoms out-
side the Rome III criteria (i.e., IBS-like symptoms, GERD-
like symptoms, and other less obviously clustered dys-
peptic symptoms), as well as one additional symptom
identified from the qualitative research reports in the lit-
erature (i.e., vomiting). Except for vomiting, all of the
identified symptoms from the published qualitative
research reports were also specified in the Rome III criteria
[3]. Heartburn or GERD-like symptoms identified in the
symptoms literature review have been shown to co-occur
with dyspeptic symptoms and are deemed interconnected
to the key diagnostic symptoms of FD. Further, patients
with FD frequently experience IBS-like symptoms, making
it difficult to separate IBS from the symptoms used as
diagnostic criteria of FD. Therefore, it is likely that future
qualitative research soliciting direct patient reports of
symptoms in the population of patients with FD will elicit
not only the symptoms specified in the Rome III criteria but
also a larger set of symptoms as conceptual saturation is
achieved. Whether the conceptual framework of a future
PRO instrument should adhere to a narrow subset of dis-
ease-defining symptoms or attempt to incorporate a broader
range of FD-predominant symptoms will be informed by
qualitative and quantitative data from interviews with
patients with FD.
Sixteen instruments were identified in the literature
search for existing PROs used in populations with FD. Of
these, three were found to measure all seven core symp-
toms of FD as defined by the Rome III criteria: the DSSI,
NDI, and SF-NDI. However, when these three instruments
were evaluated in light of regulatory evidentiary recom-
mendations [5], several issues were identified that could
jeopardize qualification of the instruments for substantia-
tion of a labeling claim.
Firstly, all three instruments have a recall period of
2 weeks, which is longer than recommended by the FDA
PRO Guidance (Sect. D.1, Content validity: recall period)
[5]. Generally, the appropriateness of the recall period
should be established for the population, disease state, and
application of the instrument and, more specifically, factors
such as the variability, duration, frequency, and intensity of
the concept measured should be considered. Therefore,
given the inherent variability of FD symptoms, the
advantage of momentary assessment in reducing recall
bias, and the stated objective of regulatory acceptance, a
2-week recall period would not likely be considered
acceptable.
Secondly, the NDI and SF-NDI assess all symptoms in
terms of frequency, intensity, and bother. Certain symp-
toms, such as vomiting, lend themselves to assessment by
certain dimensions (e.g., frequency) better than others (e.g.,
intensity); bother, as an evaluative concept, is complex and
may encompass aspects of symptom frequency, severity,
and impact. Further, qualitative evidence of the content
validity of these instruments is unavailable in the empirical
literature. In particular, although concepts were elicited
from patients during the development of these instruments,
no evidence that a conceptual framework was developed or
that conceptual saturation was achieved is evident. Lastly,
there is a lack of evidence regarding cognitive debriefing
across all three instruments. For comparison, a review of
the literature conducted by Ang et al. [32] to identify
studies of patients with FD that employed clinical outcome
assessments similarly concluded that no existing instru-
ments appeared to be sufficiently content valid for use in a
Rome III-defined FD trial.
In light of the preliminary conceptual model and the
deficiencies of these existing instruments with respect to
the approach outlined in the FDA PRO Guidance, funda-
mental modifications and new documented evidence would
be a prerequisite for deploying any of these instruments in
a biopharmaceutical development program targeting an
FDA-approved product label. Therefore, in consideration
of the clear clinical need, the WG recommends the
development of a new PRO instrument to assess FD
symptoms and, in particular, the assessment of symptom
improvement. The conceptual model for FD symptoms
derived from our symptoms literature review can serve as a
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foundation for the future qualitative research necessary for
the development of such an instrument, and will be
informed by data from qualitative interviews in patients
with FD as well as refined throughout the instrument
development process.
The next step in the development of a new FD symptom-
focused PRO instrument is to conduct concept elicitation
interviews among patients with a Rome III-confirmed FD
diagnosis to identify and document a comprehensive set of
symptoms from the patient perspective. To this end, the
WG has developed a semi-structured interview guide based
on the present work to facilitate qualitative research in a
carefully selected group of patients with FD, which will
provide documented evidence suitable for qualification
under the FDA’s DDT program [33]. As it is evident that a
number of symptoms within the conceptual model devel-
oped from the literature overlap with those of other func-
tional gastrointestinal disorders, key objectives of future
concept elicitation interviews will be to establish whether
these overlapping concepts are important and relevant
symptoms from the perspective of patients with FD, and to
gather evidence that development of a well-defined and
reliable patient-reported measure to assess treatment ben-
efit is possible in FD.
5 Limitations
The preliminary conceptual model currently includes
concepts assessed by PRO instruments that, although used
in studies to assess FD symptoms, were not initially
developed in an FD population. The FDA PRO Guidance
[5] outlines the importance of ensuring that ‘‘the items and
domains of an instrument are appropriate and comprehen-
sive relative to its intended measurement concept, popu-
lation, and use’’. Therefore, it is possible that qualitative
research may demonstrate that some of the concepts cur-
rently included in the conceptual model are not important
or relevant to patients with FD.
Owing to our chosen eligibility criteria, articles were
excluded if they concerned FD in a pediatric population,
concerned symptom assessment in a mixed population (i.e.,
population was not exclusive to patients with FD and
included patients with other gastrointestinal conditions),
reported data on patients recruited into a study based on
pre-Rome II criteria, reported FD symptoms without
specifying a qualitative methodology or naming a specific
questionnaire by which they were collected, focused on
questionnaires used for diagnostic purposes only (not study
endpoints), or were derived from non-peer-reviewed
research (e.g., conference proceedings or dissertations).
Therefore, it is possible that instruments that could have
been modified and redeveloped may have been excluded.
However, in light of the results of our instrument evalua-
tion, this possibility appears unlikely.
6 Conclusion
No existing PRO instruments were identified that assessed
all seven core Rome III symptoms of FD and adhered to
principles consistent with the instrument development
approach outlined in the FDA PRO Guidance for sup-
porting product labeling. In light of these findings, the WG
recommends the development of a new PRO instrument to
measure FD symptoms, and provides a preliminary con-
ceptual model for consideration in the requisite qualitative
research.
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